Israeli Scientists Claim They're On The Path To A Cure For Cancer


Regimens us, most people cocktail of drugs, it all attack different aspects of how cancer cells. So that is certainly. And a very, yeah. Worthwhile. Coach and the problem with that is often do combine toxicity of combinations. So this suggestion because the targeted to cancer cells that would eliminate or drastically reduce that, so, you know, that's that's that's galore promise. The other aspect civically mentioned stem cells with a lot of the. Embryonic stem cells hero the control Vesey about right? Sales within the cancer that populate the other cells in kind of the mothership to the cancer. If you like. And traditional chemotherapy drugs. Sit targeted rapidly dividing cells don't often target sales. Very well. Because they know quickly multiplying the ones that can chemotherapies do a good job on on killing off. So there are some great elements to it. But. History. More details and. And until that point I have a sort of healthy skepticism. Dr Nigel Brockton is with us the director research from the American Institute for cancer research. We're reacting to quote such as this from Dan. Era door. I believe it is who's the chairman of the board for the accelerated. Evolution biotechnologies limited. This is a company founded in two thousand it's a small team of Israel. Scientists saying we believe we will offer New Year's time a complete cure for cancer from what you know yourself, sir. From other people you've talked to in the last twenty four hours. What do you know about this group of scientists? I I knew very little I know what I've done a bit of googling around. I even PubMed it's been the database that keeps all the scientific literature in my creek search on there. I couldn't find anything about what he'd done so he's been over aging an industry, which operates kind of outside academia largely. So it's not as transparent. A world in which to get your insights, which you know, when you're developing a product, and you're trying to protect that intellectual property that that's understandable. The other thing is they can very well saying we're gonna kill Kansas Kansas is no one disease. There are many kinds is actually that we do a pretty good job of curing right now. And certainly as a whole, and we are still struggling to to cure cancer. And that's partly why I are so focused on prevention, and what individual people can do to reduce the risk of cancer and improve their outcomes after diagnosis. But yeah. Percents ninety percents of the research dollas spent are on treatment because. That's what becomes the priority. When people are diagnosed, right? Yeah. Not much to know at the moment. Let me ask mobile whether this will be developed in private, and I would love nothing more than a year's time. Someone said we've got the answer. Sure, you know, this very well for a couple of reasons here as the director research for the American Institute for cancer research, and you also had cancer you had it at a very young age, you still pay attention to that. So when you look at it in those two areas, what will you watch for over the next week month year years that would further convince you that they have made this amazing breakthrough in and if they would stay quiet if they would not provide further information over the next few weeks or few months is an easy to then say that would make more of a skeptical, but what they truly have. I didn't know for sure I mean, what I'd be looking for is a clinical trial to be developed and the and clinical trial dot gov is a database that lists all of the clinical trials of vast majority. Two trials are conducted across the world. And so you can search looking there for your targeting peptides, using some of the words and the description of their method, and you would. New right. Yeah. No. Something. Yeah. Have it in front of me? Yeah. And also, maybe even if there was one of the the phone companies was going to invest in it that would even if they don't release any information about the fact that they it they seen promise and. And and invested. Has to be said that that happened that does happen in lots of cases that don't pan out in the long term. I mean, we're now in the the kind of era of immune therapies and the last. Even just three to five. Yes. He's been explosion in the use of immune therapies, and in some ways extremely effective to that. There was you know, in this sort of fifteen fifteen years to five years ago. And to some extent it's still going on. But in in the last fifteen years of targeted therapies. You look at the genetics of cancer. And and try and target the the vulnerabilities of that kinds of based on which. Signaling naked in. I'm you tasted. But the problem is cancer. We see he and if find another way around that roadblock. And so although there was some initial success that approach overall treatment resistance did develop. Now this group specifically said because they're targeting multiple pathways at once they. Believe it will be. Resistance. But again, we've we've been down this road and. One of colonies, I headed a conference recently was that you know, now that we're using in unit therapies where you're using a system against the system is far better than using one one or two selected targets and. So we'll have to see what what comes dashing the washes, sir. Very important information. We'll we'll see where this goes. And I greatly. Appreciate your time. We'll reach out again. Okay. Thanks very much Dr Nigel Brockton. Again, he's the director of research for the American Institute for cancer research reacting. This report from a team viscerally. Scientists who believe they have a cure for cancer, and it will be out within a year. Let's pause anytime you want to react, you certainly can eight one eight zero seven here on W.

Coming up next